Vaccinations have been completed and Valneva expects VALOR trial outcomes to be announced in the first half of 2026, followed by regulatory submissions as planned. Pfizer aims to submit a Biologics ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

The US drugmaker is offering about 4.55 million American depositary receipts via an overnight block trade marketed between ...

Pfizer (PFE) has reportedly decided to sell its entire remaining stake in BioNTech (BNTX), showing a lack of confidence in ...

A wave of lawsuits with novel strategies show that the search for Covid vengeance — and jury awards — has gained force under ...

The clarification from the German biotech company comes on the heels of a Bloomberg report that Pfizer is considering selling ...

A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration ...

Pfizer sell 508M stake in BioNTech through an overnight block trade, marking its exit from the COVID-19 vaccine partner's equity.

Anonymized data shared with pharma will remain hidden from public after two-year legal battle, based on hidden evidence of "triangulating" the deceased's identities and assumption their relatives ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech ...

Valneva's trajectory was significantly altered in August when the U.S. Food and Drug Administration (FDA) suspended the license for its Chikungunya vaccine IXCHIQ®, citing safety concerns. This ...

A significant development emerged on November 13 when Pfizer announced it had sold 54.7% of its stake in BioNTech, retaining only $163.5 million worth of shares. This move marks a substantial shift in ...